PE20010170A1 - Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidropiran-3-carboxilicos como inhibidores de metaloproteasas - Google Patents

Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidropiran-3-carboxilicos como inhibidores de metaloproteasas

Info

Publication number
PE20010170A1
PE20010170A1 PE2000000507A PE0005072000A PE20010170A1 PE 20010170 A1 PE20010170 A1 PE 20010170A1 PE 2000000507 A PE2000000507 A PE 2000000507A PE 0005072000 A PE0005072000 A PE 0005072000A PE 20010170 A1 PE20010170 A1 PE 20010170A1
Authority
PE
Peru
Prior art keywords
inhibitors
metaloproteases
arylsulfonylamine
hydroxyamides
carboxylics
Prior art date
Application number
PE2000000507A
Other languages
English (en)
Inventor
Lawrence Alan Reiter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010170A1 publication Critical patent/PE20010170A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Abstract

SE REFIERE A DERIVADOS HIDROXIAMIDA DE ACIDOS 3-(ARILSULFONILAMINO)-TETRAHIDROPIRAN-3-CARBOXILICOS DE FORMULA I, DONDE: R1, R2, R3, R4 SON H, OH, ALQUILO C1-C6, (ALCOXI C1-C6)(ALCOXI C1-C6), ENTRE OTROS; R1 Y R2 JUNTOS FORMAN UN GRUPO CARBONILO, R3 JUNTO A R4 FORMAN UN GRUPO CARBONILO; Q ES ALQUILO C1-C6, ARILO C6-C10, HETEROARILO C2-C9, (ARILOXI C6-C10)(ALQUILO C1-C6), (ARILOXI C6-C10)(ARILO C6-C10), (ARILOXI C6-C10)(HETEROARILO C2-C9), (ARIL C6-C10)(ALQUILO C1-C6), ENTRE OTROS ESTANDO CADA UNO DE DICHOS RESTOS DE ARILO SUSTITUIDO CON FLUORO, CLORO, BROMO, ALQUILO C1-C6, ENTRE OTROS; CON LA CONDICION DE QUE CUANDO LA LINEA DE RAZON ES UN DOBLE ENLACE ENTONCES UNO DE R1 O R2 Y UNO DE R3 Y R4 NO ESTA PRESENTE, CON LA CONDICION DE QUE CUANDO UNO DE R1 O R2 ES OH EL OTRO NO ES OH, ALCOXI C1-C6, (ALCOXI C1-C6)(ALCOXI C1-C6) ENTRE OTROS. CUANDO UNO DE R3 Y R4 ES OH, EL OTRO NO ES OH, ALCOXI C1-C6, ENTRE OTROS; SON COPUESTOS PREFERIDOS HIDROXIAMIDA DEL ACIDO 3-[4-(4-FLUOROFENOXI)BENCENOSULFONILAMINO]TETRAHIDRO-3-CARBOXILICO, HIDROXIAMIDA DEL ACIDO 3-[4-(4-CLOROFENOXI)BENCENOSULFONILAMINO]TETRAHIDROPIRAN-3-CARBOXILICO. EL COMPUESTO I ES INHIBIDOR DE LAS METALOPROTEASAS Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ARTRITIS, CANCER, ENFERMEDAD INFLAMATORIA DEL INTESTINO, ENFERMEDAD DE CROHN, ENFISEMA, ENFERMEDAD DE ALZHEIMER
PE2000000507A 1999-05-28 2000-05-26 Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidropiran-3-carboxilicos como inhibidores de metaloproteasas PE20010170A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13653099P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
PE20010170A1 true PE20010170A1 (es) 2001-02-27

Family

ID=22473239

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000507A PE20010170A1 (es) 1999-05-28 2000-05-26 Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidropiran-3-carboxilicos como inhibidores de metaloproteasas

Country Status (22)

Country Link
US (1) US6197810B1 (es)
EP (1) EP1181286B1 (es)
JP (1) JP3784645B2 (es)
AT (1) ATE254119T1 (es)
AU (1) AU4424000A (es)
BR (1) BR0011539A (es)
CA (1) CA2375524C (es)
DE (1) DE60006523T2 (es)
DK (1) DK1181286T3 (es)
DZ (1) DZ3046A1 (es)
ES (1) ES2208315T3 (es)
GT (1) GT200000079A (es)
HN (1) HN2000000074A (es)
MA (1) MA26738A1 (es)
MX (1) MXPA01012265A (es)
PA (1) PA8495901A1 (es)
PE (1) PE20010170A1 (es)
PT (1) PT1181286E (es)
SV (1) SV2001000086A (es)
TN (1) TNSN00111A1 (es)
UY (1) UY26167A1 (es)
WO (1) WO2000073295A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
IL151125A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
MXPA02009312A (es) * 2000-03-21 2003-03-12 Procter & Gamble Inhibidores de las metaloproteasas que contienen cadenas laterales heterociclicas.
EP1265865A2 (en) 2000-03-21 2002-12-18 The Procter & Gamble Company Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
US7019376B2 (en) * 2000-08-11 2006-03-28 Reflectivity, Inc Micromirror array device with a small pitch size
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
US20050058611A1 (en) * 2003-08-22 2005-03-17 L'oreal Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight
HUE025013T2 (hu) * 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
CA2804173C (en) 2010-07-09 2015-01-13 Pfizer Limited Sulfonamide nav1.7 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US6303636B1 (en) 1997-02-03 2001-10-16 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico

Also Published As

Publication number Publication date
MXPA01012265A (es) 2002-07-30
TNSN00111A1 (fr) 2002-05-30
WO2000073295A1 (en) 2000-12-07
SV2001000086A (es) 2001-11-08
JP2003500485A (ja) 2003-01-07
CA2375524A1 (en) 2000-12-07
GT200000079A (es) 2001-11-16
BR0011539A (pt) 2002-02-26
DE60006523D1 (de) 2003-12-18
PA8495901A1 (es) 2002-08-26
MA26738A1 (fr) 2004-12-20
PT1181286E (pt) 2004-02-27
DZ3046A1 (fr) 2004-03-27
HN2000000074A (es) 2001-02-02
US6197810B1 (en) 2001-03-06
DE60006523T2 (de) 2004-08-12
ES2208315T3 (es) 2004-06-16
EP1181286A1 (en) 2002-02-27
DK1181286T3 (da) 2004-02-16
UY26167A1 (es) 2000-12-29
EP1181286B1 (en) 2003-11-12
CA2375524C (en) 2006-11-28
AU4424000A (en) 2000-12-18
JP3784645B2 (ja) 2006-06-14
ATE254119T1 (de) 2003-11-15

Similar Documents

Publication Publication Date Title
BR9912944A (pt) Inibidores de tace
YU5201A (sh) Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp
AP9801174A0 (en) Cyclic sulfone derivatives.
TR200002951T2 (tr) (4-Arilsülfonilamino)-tetrahidropiran-4-karboksilik asit hidroksamitler
MY121754A (en) Arylsulfonylamino hydroxamic acid derivatives
NO20025792D0 (no) Kinazolinderivater for behandling av tumorer
WO2002036135A3 (en) Compositions for antitumour treatment containing ecteinascidin 743
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
PE20010170A1 (es) Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidropiran-3-carboxilicos como inhibidores de metaloproteasas
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
SE0003476D0 (sv) Compounds
HN2000000052A (es) Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
RU2003105901A (ru) Противовоспалительное лекарственное средство

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed